Produced and funded by UCB. Prescribing Information and adverse event reporting can be found at the bottom of the page

  • Products
  • Contact Us
  • Sitemap

Sitemap

  • How to prescribe
  • International Consensus Update LGS management
  • Dosing
  • DS and LGS
  • Rystiggo® (rozanolixizumab)
  • Privacy policy
  • Terms and conditions
  • Cookie Policy
  • Homepage
  • Contact Us
Prescribing information
(external links)
Fintepla®▼ (fenfluramine)
Rystiggo®▼ (rozanolixizumab)
Zilbrysq®▼ (zilucoplan)

  • Privacy Policy

  • Terms and Conditions

  • Sitemap

  • Cookie Policy

Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or, via the MHRA Yellow Card App in the Google Play or Apple App Store. Adverse events should also be reported to UCB Pharma Ltd. Email: UCBCares.UK@UCB.com or 0800 2793177.
This website is created and funded by UCB Pharma Ltd and contains promotional content.
This website is intended for UK healthcare professionals only.
©2026 UCB Pharma Ltd. All rights reserved.